Loading patent…
AssigneesSuzhou RoyalTech Med CO., Ltd, Shanghai RoyalTech Med CO., Ltd
InventorsNan Dai, Yonggang Zhao
Estimating the term…
A tumor immunotherapy composition based on modified cells, in particular antigen-presenting cells activated by means of attenuated Listeria monocytogenes, a preparation method therefor and an application thereof. Attenuated Listeria monocytogenes carrying a specific antigen plasmid is used to activate antigen-presenting cells, thereby activating MHC antigen presenting properties and a series of cellular immune responses in vivo so as to achieve the purpose of anti-tumor therapy. The described technical solution may specifically activate macrophages and/or dendritic cells, thereby eliciting a series of specific anti-tumor immune responses. The operation process does not require genetic modification of autologous cells, is not limited by tumor type, and operations of the overall process are simple, easy-to-implement and reproducible. The tumor immunotherapy composition of the present disclosure may activate a series of anti-tumor immune responses in vivo, thereby greatly shortening the treatment process and significantly improving targeting ability and safety.
A population of antigen-presenting cells obtained by contacting said antigen-presenting cells with a recombinant Listeria that is attenuated, wherein said recombinant Listeria comprises:
A method for inducing an immune response in a subject, wherein said method comprises
A method for activating a population of antigen-presenting cells, wherein said method comprises
Dependencies are inferred from the claim text.